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Rilpivirine, a recently developed drug of choice for initial treatment of HIV-1 infection, can greatly reduce HIV-
related inflammation, but in turn, may be associated with adverse secondary effects, including disturbances in 
lipid metabolism and ultimately in adipose tissue distribution and function. In recent years, research findings on 
the benefits of anti-oxidant foods and supplements have been employed in counter-acting both oxidative stress 
as well as inflammation in order to reduce the adverse side effects of anti-retroviral therapy. One such natural 
flavonoid which possesses anti-inflammatory and anti-oxidative properties is quercetin. This study investigated 
the effect of quercetin in overcoming the side effects incurred due to rilpivirine administration. The results show 
substantial reduction in the accumulation of triglyceride levels in a dose- and time- dependent manner for 
adipose cells treated with either rilpivirine or quercetin alone and in combination, as evidenced by 
morphological pictures and quantitative measurement of triglycerides throughout the differentiation process. 
Levels of inflammatory markers such as resistin and IL-8 were increased as compared to the untreated cells. No 
significant changes in leptin were observed on treatment of adipose cells with rilpivirine alone and its levels 
were almost comparable to control. Levels of oxidative markers like superoxide dismutase, catalase and 
glutathione were also decreased. Treatment with quercetin showed a decrease in the inflammatory status and an 
increase in the oxidative status of adipose cells, thereby, exhibiting its anti-inflammatory and anti-oxidative 
properties. However, further assessment of lipid metabolism and adipose tissue function in patients administered 
with rilpivirine-based regimes is advisable considering that totally neutral effects of rilpivirine on lipid 
homeostasis cannot be anticipated from the current study in vitro. It is concluded that rilpivirine causes an anti-
adipogenic and pro-inflammatory response pattern but only at high concentrations, whereas quercetin has been 
observed to decrease inflammation and restore the levels of anti-oxidant enzymes.  
INTRODUCTION 
The use of antiretroviral treatment for HIV infection has radically transformed the prognosis of HIV infected 
patients from terminal illness to a chronic manageable condition [1,2]. Long-term treatment of HIV 1-infected 
patients with antiretroviral drugs may result in the appearance of several secondary effects, the most frequent 
being the lipo-dystrophy syndrome [3]. Lipo-dystrophy is associated with both morphological (lipo-atrophy, 
lipo-hypertrophy) and metabolic (dyslipidemia, glucose intolerance, hypertension, endothelial dysfunction and 
atherosclerosis) alterations, which may occur singly or in combination. Moreover, it is associated with an 
increased risk of diabetes and cardiovascular diseases (CVDs). Adipocyte inflammation, oxidative stress and 
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macrophage infiltration, as well as altered adipocyte function may be considered as major contributors in the 
development of HIV associated lipodystrophy syndrome. The adipocyte, therefore, represents a plausible target 
for treatment. Although surgical treatments as well as pharmacological interventions have shown some effects, 
their use is associated with numerous adverse side effects and complications [4-7]. As such, lifestyle 
modifications may provide useful alternatives for managing the lipodystrophy syndrome, owing to their safety 
and tolerability. 
The World Health Organization (WHO) recommends that dietary interventions should be part of all HIV/AIDS 
control and treatment program as it is believed that adequate nutrition can improve adherence to anti-retroviral 
therapy (ART) and its effectiveness. It may also help to tackle metabolic abnormalities in people living with 
HIV/AIDS [8]. In 1989, WHO had declared the necessity to assess ethno-medicines and other natural products 
for the management of HIV/AIDS. To quote: “In this context, there is need to evaluate those elements of 
traditional medicine, particularly medicinal plants and other natural products that might yield effective and 
affordable therapeutic agents. This will require a systematic approach” [9,10]. Moreover, since these phyto-
medicines are not fairly expensive and have less side effects, then they are now retrieving patient approval [11, 
12]. The use of complementary and alternative medicines, including herbal medicines, is common among 
individuals with HIV and the reported prevalence of herbal remedies use by HIV-infected individuals in the 
United States varies between 12% and 27.2 % [13-15]. Surveys have revealed that nearly 67 % of HIV-infected 
patients receiving ARV therapy also take a natural health product [16]. Most common among these are vitamins 
and some flavanoids [17]. The major reasons reported by HIV-infected patients for using these complementary 
alternative medicinal modalities are a perceived additional efficacy, an increase in quality of life, a reduction of 
adverse effects of ARV therapy, and a feeling of control [18]. 
Rilpivirine (Trade name: Edurant), a prescription medicine approved by the U.S. Food and Drug 
Administration (FDA) is used for the treatment of HIV infection in adults and children 12 years of age and 
older having a viral load (number of HIV RNA copies /mL of blood) of 100,000 copies/mL or less at the start of 
treatment [19]. It belongs to a class (group) of HIV drugs called non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) and acts by binding directly to the enzyme at a site different from the nucleoside binding component, 
thereby causing an allosteric inhibition of the transcriptase. On the other hand, quercetin, a plant pigment, is a 
potent antioxidant flavonoid found mostly in onions, grapes, berries, cherries, broccoli, and citrus fruits. It is a 
versatile antioxidant known to possess protective abilities against tissue injury induced by various drug 
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toxicities. It is also a well-recognized bioflavonoid known for its anti-inflammatory, antihypertensive, anti-
obesity, anti-hyper-cholesterolemic and anti-atherosclerotic activities [20, 21]. A number of cell culture studies 
 investigating the potential anti-obesity effect of quercetin on obesity found that in addition to the inductive 
effect on lipolysis, quercetin can also suppress lipogenesis by reducing the incorporation rate of fatty acids into 
adipocyte triacylglycerols and by inhibiting the gene expression levels of fatty acid synthase (FAS) and the 
activity of acetyl-CoA carboxylase (ACC). Animal studies showed that quercetin can transiently increase energy 
expenditures which may relate to the upregulation of UCP-1. It also exhibited anti-inflammatory effects on 
adipose tissue and was reported to reduce the levels of inflammatory markers IFNγ, TNFα, IL-1, and IL-4 in 
mice. It suppressed the accumulation and activation of immune cell and improves mitochondrial functions in 
adipose tissue of HFD-induced obese mice by increasing the levels of oxidative stress-sensitive transcription 
factor and antioxidant enzymes. In addition to cell culture and animal studies focused on the beneficial effects of 
quercetin in obesity, a limited number of human studies and clinical trials have been performed to evaluate the 
effects of quercetin on obesity treatment. These studies demonstrated that quercetin significantly decreased the 
total body fat, body mass index (BMI), waist circumference and triacylglycerol concentration. The present study 
reports that rilpivirine alters adipogenic differentiation, induces expression of proinflammatory cytokines and 
alters intracellular redox status in adipose cells. Quercetin, however, exhibits beneficial nutritional effects by 
overcoming the adverse effects.  
MATERIALS AND METHODS 
Cell culture, seeding and proliferation  
To model the effect of the antiviral drug rilpivirine (10-20 µM), human subcutaneous pre-adipocytes purchased 
from Lonza (Cat. # PT5001) were used either alone or in the presence of an anti-inflammatory flavanoid, 
quercetin (50 µM). Pre-warmed (37ºC), supplemented medium was used for the culturing of pre-adipocytes. It 
was prepared by adding the entire contents of the fetal bovine serum (FBS), L-Glutamine and GA-1000 
SingleQuotsTM to the bottle of Pre-adipocyte Basal Medium-2. The final concentrations of the supplements were 
10%, 2 mM, 30 µg/ml and 15 ng/ml, respectively. Thawed cell suspension was added to 50 ml of pre-warmed 
Pre-adipocyte Growth Medium-2 and centrifuged at 300 x g for 10 minutes at room temperature. The cells were 
then washed leaving a minimum of 1 ml of wash at the bottom of the tube. A total of 20 µl of the cell 
suspension was finally diluted with an equal amount of 0.4% trypan blue. Cell count was done using 
hemocytometer to determine percent viability.  
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For the expansion of cells prior to use for assays, the pre-adipocytes were plated with approximately 9,000 cells/ 
cm2 in 0.2 ml medium/ cm2 growth area in tissue culture flasks. The flasks were then placed in CO2 incubator 
(Forma™ Series II 3110 Water-Jacketed incubator from Thermo Fisher Scientific) maintained at 37ºC and 5% 
CO2. The pre-adipocytes appeared round when first plated and within four hours, greater than 90% of the cells 
began to flatten and elongate. Within 24-36 hours the cells were adherent, elongated and spindle shaped. As 
they began to further divide, they attained a rounded shape. The cultures were fed every 3-4 days after plating. 
For sub-culturing, the spent media were aseptically removed and discarded from the flasks followed by washing 
of the attached cell layer with Dulbecco’s Phosphate Buffered Saline. Appropriate volume of Trypsin-EDTA 
solution was then added to cover the cell monolayer (approx. 25 ml/cm2). The plates were incubated at room 
temperature for 3 minutes and the cells were then observed under the microscope. Once >90 % of the cells were 
rounded and detached, approximately 0.2 ml/cm2 of temperature equilibrated Pre-adipocyte Growth Medium-2 
was added to each flask. To remove the trypsin, the cells were centrifuged at 300 x g for 10 minutes at room 
temperature and the cell pellet was re-suspended in a minimal volume of temperature equilibrated growth 
medium. The total number of cells was counted using a haematocytometer. Differentiation of pre-adipocytes 
into mature adipose cells was induced by the addition of Adipocyte Differentiation Medium for a period of 8 
days. 
 
The present study investigated the effect of rilpivirine alone (10-20 µM) and then in combination with quercetin 
(50 µM). The process was initiated on day 0 and continued throughout the adipocyte differentiation period of 8 
days. Stock solutions of treatment drugs were prepared in DMSO. They were then aliquoted and stored at -20ºC 
prior to use. Working solutions of the treatment drugs were prepared in pre-adipocyte growth medium-2 by 
diluting them further with differentiation medium. 
  Lactate dehydrogenase (LDH) Assay for the measurement of cell cytotoxicity 
 CytoTox 96 kit from Promega was used to determine the potential cytotoxic effects of the two drugs on 
differentiating human pre-adipocytes after exposure to cells for 15 days. The assay measured the appearance of 
LDH, a stable cytocyclic enzyme normally released upon cell lysis, in the cell culture medium. The released 
LDH in culture supernatants was measured with a 30-minute coupled enzymatic assay, which resulted in the 
conversion of a tetrazolium salt (iodonitro-tetrazolium violet; INT) into a red formazan product. The amount of 
colour formed was proportional to the number of lysed cells. Cell viability was assessed on day 3 and day 15 for 
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both the drugs, alone and in combination, for all concentrations used in the study. Following experimental 
treatment, supernatant samples were transferred to a 96 well plate and an equal volume of CytoTox 96® 
Reagent was added to each well and incubated for 30 minutes. Stop Solution was added, and the absorbance 
signal was measured at 490 nm using a plate reader.  
Adipo-Red Staining and Quantitative measurement of triglyceride accumulation 
Visualization and quantification of intracellular lipid droplets was done using AdipoRed™ reagent following the 
manufacturer’s protocol. AdipoRed™ stain was used to determine the effects of test compounds on the 
differentiation of adipocyte precursors as characterized by the accumulation of intracellular triglycerides. Cells 
were seeded at 10,000/cm2 of the plate surface area in appropriate volumes (2-3 ml/well) of cell culture media. 
Immediately prior to the assay, each plate was rinsed with PBS followed by the addition of AdipoRed™. The 
plate was then incubated for 10-15 minutes. The fluorescence was measured with excitation at 485 nm and 
emission at 572 nm.  
Quantitative Measurement of Adipokines and Cytokines  
Immuno-based human Elisa kits commercially available from R&D Systems were used to quantitatively 
measure the adipocytokines (adiponectin, leptin, resistin, interleukin-8) released by adipocytes and accumulated 
in the cell culture medium at the end of 8 days of differentiation process. To prepare standards for all assays, 
each vial was reconstituted with 0.5 ml of reagent diluent. A seven-point standard curve using 2-fold serial 
dilutions was prepared as described by the manufacturer.  
To prepare the micro-plate for assay, the captured-antibody was diluted to the working concentration in PBS 
without carrier protein and a volume of 100 ml was immediately coated onto each well. The plate was then 
sealed and incubated overnight at room temperature. Each well was aspirated and washed 3 times with a 400 µl 
volume of wash buffer using an auto washer (HydroFlex™ micro-plate washer from Tecan). Blocking was done 
by adding 300 μl of reagent diluent to each well. The plate was incubated at room temperature for 1 hour.  
For the assay, a volume of 100 μl of either sample or standards, in duplicates, were added to each of the 
designated wells and incubated for 2 hours at room temperature. This was followed by the addition of 100 μl of 
the detection antibody. A volume of 100 μl of the working dilution (1:200) of Streptavidin-HRP was added to 
each well and incubated for 20 minutes at room temperature. Thereafter, aspirate/wash steps were repeated. A 
volume of 100 μl of substrate solution was added to each well and incubation was done at room temperature for 
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20 minutes. Any exposure to direct light was avoided. A volume of 50 μl of stop solution was added to each 
well and optical density was determined immediately, using a micro plate reader (Molecular Devices from Life 
technologiesTM equipped with Softmax pro7 Version 4.3 software) set to 450 nm. 
For obtaining the results, average zero standard optical density was subtracted from mean absorbance of each set 
of duplicate standards, controls and samples. Standard curve was prepared by plotting the mean absorbance for 
each standard on the y-axis against the concentration on the x-axis and drawing a best fit curve through the 
points on the graph. Sample concentrations were calculated using the equation of the standard curve. 
Quantitative measurement of oxidative stress markers 
Markers of oxidative stress (Superoxide dismutase, Glutathione, Nitric oxide and Catalase) were quantified 
using the cell lysates from the cultures using commercially available kits. 
 Superoxide Dismutase (SOD) levels 
Superoxide Dismutase Assay kit (Cat. # 706002) purchased from Cayman chemicals was used to determine the 
SOD levels. Standard and sample wells were prepared by adding 200 μl of the diluted radical detector and 10 μl 
of SOD standard or sample per well. The reaction was initiated by adding 20 μl of diluted xanthine oxidase to 
all the wells. The plate was then kept on a shaker for 30 minutes at room temperature and absorbance was read 
at 440-460 nm using a plate reader. Average absorbance for each standard and sample was calculated by 
subtracting the sample background absorbance from the sample. Linearized rate was obtained by dividing 
standard A’s absorbance by itself and then with absorbance values of all other standards and samples. This 
linearized SOD standard rate was plotted as a function of final SOD Activity. SOD activity was calculated by 
using the equation obtained from the linear regression of the standard curve and substituting the linearized rate 
for each sample.  
 Glutathione Assay  
This assay was performed using the Glutathione Assay Kit from Sigma-Aldrich (Cat. #CS0260) following the 
manufacture’s protocol. Standards were prepared by adding 50 μM of glutathione solution in the first well and 
then subsequently diluting it serially. In order to prepare the samples for the assay, cell extracts were washed 
with PBS and at least 1x108 cells were suspended per ml of PBS and transferred to a micro centrifuge tube. 
Centrigugation was done at 600 x g and supernatant was removed. The volume of the pellet was measured and 3 
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volumes of 5% SSA solution was added. The suspension was then freeze-thawed twice using liquid nitrogen and 
a 37°C water bath.  It was then left for 5 minutes at 2–8 ºC. The extract was centrifuged at 10,000 x g for 10 
minutes and the volume of the supernatant was measured. For the assay procedure, plate reader was set to 412 
nm with kinetic read at 1-minute intervals for 5 minutes. The first 2 wells contained only 10 µl of the 5 % 5-
sulfosalicylic acid solution as a reagent blank. A total of 10 µl glutathione standard solutions and unknown 
samples in duplicate were added into designated wells of the plate. A volume of 150 µl of working mixture was 
added to each well followed by 5 minutes of incubation at room temperature. After incubation, 50 µl of diluted 
NADPH solution was added to each well and absorbance was measured. To compute the results, values from the 
glutathione standard solutions were used to determine the standard curve and calculate A412 /min equivalent to 
1 mole of reduced glutathione per well. 
 Nitric Oxide Assay 
Cayman's Nitrate/Nitrite colorimetric Assay kit (Cat. #780001) was used for the measurement of total nitric 
oxide following the manufacturer's protocol. A volume of 200 µl of assay buffer (to be used as blank) and 80 µl 
of sample was added to the wells. This was followed by the addition of 10 µl of the Enzyme Cofactor Mixture 
and 10 µl of the nitrate reductase mixture to each of the wells (standards and unknowns). The plate was covered 
and incubated for 2 hours at room temperature. After the incubation time, a volume of 50 µl of Griess Reagent 
R1 followed by 50 µl of Griess Reagent R2 was added to each of the wells. The plate was left for 10 minutes at 
room temperature for the development of colour. Absorbance was read at 540 nm using a plate reader. Mean 
absorbance values of the blank wells were subtracted from the absorbance values of all the other wells. 
Corrected absorbance values at 540 nm were plotted as a function of nitric oxide concentration.  
Catalase Activity 
Cayman's Catalase Kit (Cat. # 707002) was used to determine the enzyme activity of catalase using the cell 
lysate. Formaldehyde standard wells were prepared by adding a volume of 100 µl of diluted assay buffer of 
standard tubes in each of the designated wells on the plate. Sample wells were prepared by addition of 100 µl of 
diluted assay buffer, 30 µl of methanol, and 20 µl of sample. Reaction was initiated by adding 20 µl of diluted 
hydrogen peroxide to all the wells. The plate was covered and incubated on a shaker for 20 minutes at room 
temperature. The reaction was terminated by adding 30 µl of potassium hydroxide followed by addition of 30 µl 
of catalase purpald (Chromogen) to each well. Incubation was done for 10 minutes at room temperature on the 
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shaker. After this, a volume of 10 µl of catalase potassium periodate was added to each well and incubation was 
done for 5 minutes at room temperature. Absorbance was read at 540 nm using a plate reader. The rate of the 
reaction was determined by subtracting the average absorbance of each standard and sample from the average 
absorbance of standard A. The corrected absorbance of standards was plotted as a function of final 
formaldehyde concentration (µM). Formaldehyde concentration of the samples was calculated using the 
equation obtained from the linear regression of the standard curve after substituting corrected absorbance values 
for each sample.  
Statistical analysis 
Data were analyzed statistically using SPSS Version 25 software. The means of the data are presented with the 
standard deviation (SD). The results were analyzed using one-way ANOVA to determine the significance of the 
mean between the groups. Values of p< 0.05 were considered significant. 
RESULTS  
Cyto-toxicity measurement using lactate dehydrogenase assay 
The human subcutaneous pre-adipocytes were seeded at a density of 2 × 104 cells per well in 24-well plates and 
cultured until 90 % confluence. They were then treated with various concentrations (10-20 µM) of rilpivirine or 
quercetin (50 µM) either alone or in combination for a period of 15 days. As an indicator of cytotoxicity, the 
cytoplasmic enzyme lactate dehydrogenase (LDH) was quantified in the culture supernatant of the control as 
well as treated differentiating adipose cells on day 3 and day 15 of culture. The percentage of viable cells was 
calculated by defining the cell viability without treatment as 100 %. The results are shown in Figure 1 for (A) 3 
days and (B) 15 days. The results presented in figure I a show no significant (p>0.05) changes in the viability of 
cells when treated with various concentrations of either rilpivirine or quercetin either alone or in combination 
for day 3 of culture.  The results presented in figure I b show that rilpivirine at lower concentrations (10 µM and 
15 µM) and quercetin at 50 µM did not alter the viability rate of the cells. However, at a concentration of 20 µM 
rilpivirine, a slight and significant (p<0.05) decrease in the cell viability was observed indicating its effect at 
higher doses. A combination of rilpivirine and quercetin at concentrations of 20 µM and 50 µM, respectively, 









Fig I Bar graph showing the effect of either rilpivirine or quercetin either alone or in combination on the 
cell viability as measured by LDH on day 3 and day 15 of culture 
Human subcutaneous adipose cells were treated with various concentrations of indicated drugs either alone and in combination. Cyto-toxicity was expressed as the 
percentage of LDH activity in the medium as compared to control on day 15 of incubation. The results represent mean ± SD of 3 parallel cell culture experiments; * p<0.05 
was considered significant. 
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Fig II Representative images (A-I) showing the progression of adipogenesis as indicated by lipid 
formation for human adipose cells in culture 
Human subcutaneous adipose cells were differentiated and treated with different concentrations of either rilpivirine or quercetin individually and then in combination. 
Images were taken for the 5th, 8th, 11th and 15th day of cells in culture at 20x magnification using a fluorescence microscope. Staining was done using adipored to visualize 
lipid content. Images are typical of 3 such different experiments in duplicate. These images reveal the following: A). Undifferentiated and untreated (no drugs) adipose cells.  
B). Differentiated and untreated (no drugs) adipose cells. C). Adipocytes differentiated and treated with 10 µM of rilpivirine. D). Adipocytes differentiated and treated with 
15 µM of rilpivirine. E). Adipocytes differentiated and treated with 20 µM of rilpivirine. F). Adipocytes differentiated and treated with 50 µM of quercetin. G). Adipocytes 
were differentiated and treated with a combination of 10 µM rilpivirine and 50 µM quercetin. H). Adipocytes differentiated and treated with a combination of 15 µM 
rilpivirine and 50 µM quercetin.I). Adipocytes were differentiated and treated with a combination of 20 µM rilpivirine and 50 µM quercetin.  
Morphological fluorescence data in figure II show the accumulation of triglyceride in pre-adipocytes cultured 
and differentiated in the presence and absence of treatment drugs either alone or in combination. Image A 
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represents undifferentiated and untreated pre-adipocyte cells in culture. These cells appeared elongated, 
fibroblast-like structure, spindle-shaped and showed no lipid accumulation. Image B represents the progression 
of pre-adipocyte cells into matured adipose cells differentiated for 15 days without any drug treatment (control). 
The process of adipogenesis progressed in a time-dependent manner as evidenced by the increasing lipid 
droplets (yellow). On day 5, almost none or very little amount of lipid droplets were observed. However, by day 
8 the cells began to attain a rounder shape and became laden with lipids. They had accumulated substantial 
triglyceride content and grew more in size and number on day 11 and 15 of culture. Images C, D and E represent 
pre-adipocyte cells treated with a dosage concentration of 10 µM, 15 µM and 20 µM of rilpivirine, respectively 
over a period of 15 days. It was observed that rilpivirine inhibited the accumulation of triglycerides in a dose- 
and time- dependent manner. The formation of lipid droplets (yellow) decreased with increasing dosage and 
time in culture. Images F represents pre-adipocytes treated with 50 µM of quercetin. Pre-adipocytes treated with 
quercetin were shown to inhibit triglyceride accumulation with increasing number of days in culture. The 
number of lipid droplets decreased from day 8 until day 15 in culture. Images G, H and I represent pre-adipocyte 
cells treated with a combination of 10 µM, 15 µM, 20 µM of estradiol and 50 µM of quercetin, respectively. 
Adipose cells treated with these combinations of drugs showed attenuation in lipid content in time- and dose- 
dependent manner. Day 8 of differentiation showed a substantial amount of triglyceride accumulation which 
almost became diminished until day 15. 
Quantitative measurement of triglycerides 
Triglycerides accumulated over the differentiation period of 15 days with drug treatments were measured 
quantitatively compared to untreated cells by staining the cells with adipored reagent and the fluorescence was 















Fig III (A-D) Bar graphs showing the effect of rilpivirine and quercetin individually and then in 
combination on the accumulation of triglyceride by human adipocytes in culture 
Human pre-adipocytes were differentiated in culture in the presence of indicated concentrations of rilpivirine and quercetin. Values represent concentration of triglyceride in 
cell supernatant for the 5th, 8th and 11th and 15th day of culture. Statistical analysis was performed using a one-way ANOVA and are presented as mean ± S.D from 
triplicate set of experiments expressed relative to values from untreated control cells; *p<0.05 **p<0.01 ***p<0.001 compared to the control. #, $, and indicate significance 
differences within the treatment groups. 
Figure III A-D shows triglyceride accumulation in differentiated mature adipose cells over a period of 15 days 
either in the absence (control) or presence of indicated concentrations of treatment rilpivirine or quercetin, alone 
or in combination. Adipose cells that were not treated with any drugs (control) showed a significant progression 
in the accumulation of triglycerides over 15 days in culture. Figure III A shows the accumulation of 
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triglycerides on the 5th day of culture. Rilpivirine at all tested concentrations induced significant (p<0.05) dose-
dependent changes in the lipid accumulation with maximum decrease at 20 µM of rilpivirine. Adipose cells 
treated with 50 µM of quercetin also evoked a slight reduction in the triglyceride levels. Combination of 
rilpivirine and quercetin decreased the triglyceride concentration in a dose dependent manner. 
The results of triglyceride accumulation were more pronounced on day 8 and day 11 of culture (see Figure III 
B/C). Rilpivirine at concentrations of 15 µM and 20 µM showed a significant (p<0.05 and p<0.01 for day 8 and 
p<0.01 and p<0.001 for day 11, respectively) decrease in triglyceride levels. Quercetin also inhibited the 
triglyceride level significantly (p<0.001). When the two drugs were combined, significant reduction in 
triglyceride levels were measured. The levels of triglyceride on day 15 (Figure III D) in the adipose cells 
showed substantial reduction (p<0.001) when treated with either rilpivirine or quercetin. This reduction was 
more prominent and significant when the two drugs were combined together.  
Overall, the results show that both rilpivirine and quercetin alone and in combination can significantly inhibit 
(p<0.05 for day 8 and p<0.001 for day 11 and 15, respectively) lipid formation and attenuate triglyceride 
accumulation in adipose cells in both dose as well as time dependent manner. 
Based on the results presented in figures II and III, the median dosage concentration at which rilpivirine 
inhibited triglyceride accumulation maximally was 15 µM. Thus, this concentration was chosen for a 
differentiation period of 8 days with 50 µM quercetin measuring a number of adipocytokines and oxidative 
stress markers using biochemical assays. 
Quantitative measurement of inflammatory adipocytokines 
Human subcutaneous adipose cells were cultured and differentiated over a period of 8 days in the presence of 
either rilpivirine or quercetin alone and in combination using maximal dose of each drug. Supernatant was 
collected on the 8th day of culture and the released adipocytokines (adiponectin, leptin, resistin, IL-8) were 
measured quantitatively. The data are presented in figure IV A-D. 





B Quantitative measurement of leptin 
 
 









Fig IV (A-D) Bar graphs showing the effect of rilpivirine and quercetin either alone or in combination on 
the release of adiponectin (A), leptin (B), resistin (C) and interleukin-8 (D) by human adipocytes in 
culture. 
Human pre-adipocytes were differentiated in the presence of indicated concentrations of drugs (15 µM rilpivirine and 50 µM quercetin). Values represent concentrations of 
released inflammatory markers in the cell supernatant for the 8th day of culture. Statistical analysis was performed using a one-way ANOVA and are presented as mean ± 
S.D from triplicate set of experiments expressed relative to values from untreated control cells; **p<0.01 ***p<0.001 compared to the control. #, $ indicate significant 
differences within the treatment groups. 
The results in figure IV A show marked significant reduction in the adiponectin concentration levels as 
compared to control when human pre-adipocytes were treated with rilpivirine alone (p<0.01).  Significant 
differences were observed in the adipocytes treated with a combination of rilpivirine and quercetin when 
compared with control (p< 0.01) as well as with quercetin alone (p< 0.01). Quercetin alone showed a significant 
(p<0.01) increase in adiponectin levels when compared to the untreated or control group. The results in figure 
IV B show small decrease in leptin level in the adipocytes treated with rilpivirine alone compared to control. 
Treatment with quercetin alone showed significant (p<0.001) decrease in leptin levels when compared to either 
control or rilpivirine alone. Adipose cells treated with a combination of rilpivirine and quercetin showed 
significant (p<0.01) decrease in the leptin levels as compared to control. The data in figure IV C show 
significant increase in resistin levels from adipose cells when treated with rilpivirine alone (p<0.05) or in 
combination with quercetin (p<0.01) as compared to control. The results also show that 50 µM of quercetin had 
no significant effect on the release of resistin compared to control. The results in figure IV D show a significant 
increase in the levels of IL-8 for adipose cells treated with rilpivirine (p<0.01) as compared to control. 
Treatment with quercetin alone showed a small but significant (p<0.01) reduction in IL-8 levels. More or less, 
the same significant reduction in IL-8 concentration in the cell supernatant was obtained when the two drugs 
were combined. 
Quantitative measurement of oxidative stress markers 
Markers of oxidative stress (nitric oxide, superoxide dismutase, glutathione and catalase) were measured 
quantitatively using commercially available kits and the data are presented in figure V A-D for drug treated 
compared to untreated cells. 





B Quantitative measurement of SOD activity   
 




D Quantitative measurement of glutathione   
 
Fig V (A-D) Bar charts showing the effect of rilpivirine and quercetin individually and then in 
combination on the release of oxidative markers by human adipocytes in culture. 
 Human pre-adipocytes were differentiated in the presence of indicated concentrations of drugs (15 µM rilpivirine and 50 µM quercetin). Values represent concentrations of 
oxidative markers in the cell lysates for the 8th day of culture. Statistical analysis was performed using a one-way ANOVA and are presented as means of ± S.D from 
triplicate set of experiments expressed relative to values from untreated control cells; *p<0.05 **p<0.01compared to the control. # represents significance difference within 
the treatment groups. 
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The data presented in figure V A show a small, but significant reduction in catalase activity in adipose cells 
treated with rilpivirine alone (p<0.01) as compared to control. In contrast, either quercetin or quercetin in 
combination with rilpivirine had do significant effect on catalase activity compared to control. The results in 
figure V B show a significant decrease (p<0.01) in SOD activity in adipose cells treated with rilpivirine alone. 
Adipose cells treated with quercetin alone showed a small, but significant (p<0.05) increase in the SOD activity. 
When rilpivirine was combined with quercetin they induced a small, but significant (p<0.05) increase in SOD 
activity compared to adipose cells treated with rilpivirine alone. Figure V C shows the levels of nitric oxide in 
adipose cells. The results show that rilpivirine alone can elicit a marked increase (p<0.05) in the nitric oxide 
levels as compared to control untreated cells. In contrast, nitric oxide levels were significantly (p<0.01) reduced 
in adipose cells treated with quercetin alone. However, when rilpivirine was combined with quercetin there was 
a small, but significant increase in nitric oxide levels (p<0.05). The results presented in figure V D show a 
significant decrease (p<0.01) in glutathione activity for adipose cells treated with rilpivirine alone. Quercetin 
alone and in combination with ripivirine evoked a marked but, significant (p<0.001) elevation in GSH activity 
as compared to control. 
DISCUSSION  
Over the last decade, the introduction of antiretroviral therapy (HAART) has dramatically decreased morbidity 
and mortality rates among HIV-infected patients [22].  However, multiple morphological and metabolic 
abnormalities including subcutaneous adipose tissue wasting (lipo-atrophy), central adipose tissue accumulation 
(lipo-hypertrophy), severe dyslipidemia and abnormalities of glucose metabolism have been observed among 
HAART-treated patients with well-controlled HIV. Previously reported data on anti-retroviral drug therapy have 
demonstrated serious metabolic consequences [23]. Although the new anti-retroviral drugs are not free of 
metabolic abnormalities, studies determining the effects on metabolic indices and body composition are limited. 
With this preview in mind, the present study investigated any detrimental effects of rilpivirine, a newly 
developed HIV drug, on human adipocytes as a model of inflammation, either alone or in combination with 
quercetin, a known plant-derived antioxidant. Firstly, the two drugs were investigated for any toxic effect on 
triglyceride accumulation and second, their ability to induce inflammation and oxidative stress.  
In order to assess the cyto-toxicity of cells, human subcutaneous adipose cells were treated with either rilpivirine 
or quercetin alone and in combination and cell viability was assessed on day 3 and day 15 of culture. The results 
show that rilpivirine at lower concentrations (10 µM and 15 µM) and quercetin at 50 µM did not alter the 
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viability rate of the cells. However, at a concentration of 20 µM, rilpivirine induced a small, but significant 
(p<0.05) decrease in the cell viability (cell death). A combination of rilpivirine and quercetin at concentrations 
of 20 µM and 50 µM, respectively, also elicited a significant (p<0.05) decrease in adipocyte viability. In the 
next series of experiments, human subcutaneous adipose cells were treated with either rilpivirine or quercetin 
alone and then in combination for a period of 15 days to determine triglyceride accumulation. Previous clinical 
trials conducted to measure the blood triglycerides, total cholesterol, low- and high-density lipoprotein in 
patients treated with rilpivirine showed substantial increases in these parameters compared to other NNRTIs 
belonging to the same class of antiretroviral drugs [24-26]. These findings were also confirmed by other studies 
[27]. The results from the present study show substantial reduction in the accumulation of triglyceride levels for 
adipose cells treated with either rilpivirine or quercetin alone and in combination, as evidenced by 
morphological pictures and quantitative measurement of triglycerides on the 5th, 8th, 11th and 15th day of the 
differentiation process. As compared to control, an altered lipid accumulation was observed in a dose- and time- 
dependent manner. Higher concentration of rilpivirine (20 µM) alone or in combination with quercetin severely 
inhibited triglyceride accumulation during adipocyte differentiation. Based on these results, a median drug 
concentration of 15 µM of rilpivirine and differentiation for a period of 8 days were chosen for further 
experiments. 
Alterations in inflammatory status of adipose tissue gives rise to a growing recognition that obesity represents a 
state of chronic low-level inflammation. In the present study, human subcutaneous adipose cells were treated 
with either 15 µM rilpivirine or 50 µM quercetin individually and in combination for a period of 8 days. The 
results show that rilpivirine can induce a marked reduction in the levels of adiponectin. Levels of other 
inflammatory markers such as resistin and IL-8 were increased as compared to the untreated cells. No 
significant change in leptin was observed on treatment of adipose cells with rilpivirine alone and its level was 
almost comparable to control. However, a significant reduction in inflammatory markers was observed for 
adipose cells treated with quercetin alone, thereby, revealing its ant-inflammatory properties. Combination of 
the two drugs markedly reduced the inflammatory makers. 
As mentioned earlier, treatment with antiretroviral therapy may often result in biochemical and physiological 
changes including oxidative damage. This may result from either the presence of free radicals or the absence of 
antioxidants. So far, sufficient evidence to substantiate the role of free radicals in mediating oxidative injury is 
not present. Data from a series of previously conducted studies have reported an increase in oxidative stress, in 
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addition to the persistent redox imbalance associated with HIV-1 infection manifested by an increase in oxidants 
and a decrease in antioxidant serum levels [28-30]. In order to reveal the oxidative status of the adipose cells 
treated with 15 µM of rilpivirine or 50 µM of quercetin either alone or in combination, a number of biomarkers 
of oxidative stress were measured quantitatively in this study. The generated oxidative profile in this study 
revealed a significant decrease in the levels of anti-oxidant enzymes like superoxide dismutase, catalase and 
glutathione in adipose cells treated with rilpivirine. The results also show a significant increase in the nitric 
oxide levels indicating its role in mitochondrial dysfunction. This reduction in the anti-oxidant species may 
possibly be attributed to the production of more oxidized metabolites deriving from the interaction between 
ROS and infected cell biomolecules [31-36]. It may further be explained and supported by several biochemical 
mechanisms, such as mitochondrial interference following treatment with ART [31, 35-36] and activation of the 
P450 hepatic system [32]. Both insufficient intake or mal-absorption of nutrients which are common attributes 
of HIV patients, may further worsen these conditions [37, 38].  
In hope to lessen the side effects of antiretroviral therapy like lipo-dystrophy syndrome, rilpivirine at a 
concentration of 15 µM was supplemented with 50 µM of an anti-oxidant, quercetin. The results of this study 
show that quercetin supplementation significantly ameliorated rilpivirine- induced oxidative stress. It was able 
to prevent injury caused by free radicals by scavenging of ROS, activate antioxidant enzymes and mitigate the 
oxidative stress caused by nitric oxide. The overall increase in the levels of anti-oxidant enzymes when 
supplemented with quercetin may be attributed to its much reported anti-oxidative and direct radical scavenging 
properties. Quercetin, thus, seems to be a powerful flavonoid for protecting the body against reactive oxygen 
species, produced during the normal oxygen metabolism or are induced by exogenous damage [39, 40].  
To summarize, soon after the introduction of the highly active antiretroviral therapy for the treatment of HIV 
infection, body shape changes and metabolic abnormalities were increasingly observed. Alongside, a 
tremendous expansion in the interest and use of traditional medicines worldwide, to combat such abnormalities 
has been on a rise. However, policies regarding the regulation of the production and use of herbs and other 
complimentary medicines and their quality, safety, efficacy and scientific evidence in relation to health claims is 
lacking. The present paper attempts to suspect pathophysiological relationships and the therapeutic 
consequences arising due to the antiretroviral drug, rilpivirine. This information may assist physicians in 
identifying individual risk factors and choosing the type of antiretroviral therapy that may minimize the 
associated metabolic changes without loss of virologic suppression.  
25 
 
Present data show that rilpivirine, at a concentration of 15 µM, displays lipodystrophic effects by elucidating an 
increase in the inflammatory markers and suppressing the anti-oxidant enzymes. However, in vitro studies using 
cells in culture have obvious limitations with respect to their relevance to the treatment of patients. It should be 
taken into account that the overall alterations in lipid metabolism in HIV-1- infected patients are thought to be 
caused not by a single drug, but by the complex interactions of a given drug with other drug components of 
antiretroviral treatment regimens, as well as underlying HIV-1-infection-related alterations. Thus, further studies 
assessing lipid abnormalities in patients treated with rilpivirine as a component of a drug cocktail will be 
necessary to confirm a metabolic-friendly effect of this drug to identify potential lipid alterations. The study 
also, for the first time, reports co-administration of rilpivirine and quercetin. The results demonstrate the 
potential abilities of quercetin to attenuate oxidative damage and decrease inflammatory markers. However, the 
study warrants further mechanistic and clinical research studies employing protein and gene expression 
adipogenic markers to develop quercetin as a proven natural and effective agent for the ART-induced prevention 
or treatment of metabolic disturbances. It is also worth considering that lipodystrophy and overall alterations of 
lipid metabolism in HIV-1-infected patients analyzed to date are caused by complex interactions of a given drug 
with other cART components, as well as with underlying HIV-1 infection-related events. 
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